Mycoplasma-induced Airway Remodeling in Human Asthma
支原体诱导的人类哮喘气道重塑
基本信息
- 批准号:7392359
- 负责人:
- 金额:$ 31.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-04-01 至 2009-03-31
- 项目状态:已结题
- 来源:
- 关键词:AftercareAsthmaBiopsyBreathingBronchiolitisCellsChronicCollaborationsCollagenCommunitiesDataDepositionEdemaEpithelial CellsExposure toFibroblastsHistopathologyHumanImmunohistochemistryInfectionInflammationInflammatoryInflammatory ResponseLaboratoriesLearningLigandsMacrolidesMediator of activation proteinMicrobiologyMucous MembraneMycoplasmaMycoplasma pneumoniaeNeprilysinNeurogenic InflammationNeurokinin APatientsPharyngitisPhenotypePneumoniaPolymerase Chain ReactionPrincipal InvestigatorProcessProductionRattusRespiratory physiologyRoleStructureSubstance K ReceptorSubstance PSubstance P ReceptorTachykininTestingTimeTissuesVascular remodelingWorkairway inflammationairway remodelingasthmatic patientimprovedin vitro Modelmast cellprogramsreceptorresponse
项目摘要
Mycoplasma pneumoniae is the cause of community acquired pneumonia in 20-30% of cases, and also causes tracheobronchitis, pharyngitis and bronchiolitis. We have recently shown that M. pneumoniae is present in the airways of patients with chronic, stable asthma, and that treatment with a macrolide improves lung function, but only in those asthmatics who demonstrate positivity for M. pneumoniae by polymerase chain reaction (PCR). Chronic M. pulmonis infection in the rat results in increased expression of the neurokinin-1 (NK-1) receptor, the ligand for substance P, increased substance P sensitivity and vascular remodeling. Additionally, substance P increases fibroblast proliferation. Preliminary data from our laboratory
demonstrates that M. pneumoniae added to epithelial cell culture induces substance P production, a new observation. Therefore, we hypothesize that infection with M. pneumoniae modifies airway responses in asthmatics by increasing substance P sensitivity and airway fibroblast proliferation, resulting in altered airway structure (remodeling) and function. Therapy with a neurokinin receptor antagonist will reduce airway edema, airway inflammation and fibroblast proliferation, particularly in those patients where M. pneumoniae is present in the airway. To test this hypothesis, we will first determine expression of the tachykinins
substance P and neurokinin A, their receptors, airway vascularity and collagen deposition in the airway mucosa of normal controls and asthmatic subjects who are PCR(+) and (-) for M. pneumoniae. Using an in vitro model of M. pneumoniae infection, we will determine the role of substance P on the bronchial epithelial cell inflammatory response and airway fibroblast proliferative response after exposure to M. pneumoniae in normal controls and PCR (+) and PCR (-) asthmatic subjects. We then will determine if substance P sensitivity is increased in PCR (+) asthmatics by performing substance P inhalational challenges, and assessing airway function and edema. Finally, we will determine changes in airway function, inflammation and edema after treatment with a neurokinin antagonist. Information learned from this proposal will allow us
to determine whether the presence of M. pneumoniae in the airway alters airway function and contributes to remodeling by increasing airway vascularity and collagen deposition. The presence of M. pneumoniae in the lower airway may result in a unique asthma phenotype that may require treatment focusing upon neurogenic inflammation.
肺炎支原体是20-30%的社区获得性肺炎的病因,也可引起气管支气管炎、咽炎和细支气管炎。我们最近证明了M.肺炎支原体存在于慢性、稳定型哮喘患者的气道中,大环内酯类药物治疗可改善肺功能,但仅适用于肺炎支原体阳性的哮喘患者。pneumoniae的PCR产物。慢性M.大鼠中的肺炎链球菌感染导致神经激肽-1(NK-1)受体(P物质的配体)的表达增加,P物质敏感性增加和血管重塑。此外,P物质增加成纤维细胞增殖。我们实验室的初步数据
证明了M.一项新的观察发现,将肺炎链球菌添加到上皮细胞培养物中可诱导P物质的产生。因此,我们推测M.肺炎通过增加P物质敏感性和气道成纤维细胞增殖来改变哮喘患者的气道反应,导致气道结构(重塑)和功能改变。用神经激肽受体拮抗剂治疗将减少气道水肿,气道炎症和成纤维细胞增殖,特别是在那些M。肺炎存在于气道中。为了验证这一假设,我们将首先确定速激肽的表达,
P物质和神经激肽A及其受体、气道血管和胶原沉积。肺炎。利用M.肺炎支原体感染后,我们将确定P物质在支气管上皮细胞炎症反应和气道成纤维细胞增殖反应中的作用。正常对照和PCR(+)和PCR(-)哮喘受试者中的肺炎链球菌。然后,我们将通过进行P物质吸入激发试验和评估气道功能和水肿来确定PCR(+)哮喘患者的P物质敏感性是否增加。最后,我们将确定用神经激肽拮抗剂治疗后气道功能、炎症和水肿的变化。从这份提案中获得的信息将使我们能够
以确定M.气道中的肺炎改变气道功能,并通过增加气道血管分布和胶原沉积而促进重塑。M的存在。下气道中的肺炎可能导致独特的哮喘表型,其可能需要集中于神经源性炎症的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Monica Kraft其他文献
Monica Kraft的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Monica Kraft', 18)}}的其他基金
The Duke Senescent Cell Evaluations in Normal Tissues (SCENT) Mapping Center
杜克大学正常组织衰老细胞评估 (SCENT) 绘图中心
- 批准号:
10689774 - 财政年份:2021
- 资助金额:
$ 31.59万 - 项目类别:
The Immunophenotyping Assessment in a COVID-19 Cohort (IMPACC)
COVID-19 队列中的免疫表型评估 (IMPACC)
- 批准号:
10204632 - 财政年份:2020
- 资助金额:
$ 31.59万 - 项目类别:
University of Arizona-Banner Health All of Us Research Program
亚利桑那大学横幅健康研究计划
- 批准号:
10338519 - 财政年份:2018
- 资助金额:
$ 31.59万 - 项目类别:
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
SARS-CoV-2 感染中的表面活性蛋白 A 和 2 型哮喘
- 批准号:
10661671 - 财政年份:2016
- 资助金额:
$ 31.59万 - 项目类别:
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
SARS-CoV-2 感染中的表面活性蛋白 A 和 2 型哮喘
- 批准号:
10261957 - 财政年份:2016
- 资助金额:
$ 31.59万 - 项目类别:
Surfactant Protein-A and Type 2 Asthma in SARS-CoV-2 Infection
SARS-CoV-2 感染中的表面活性蛋白 A 和 2 型哮喘
- 批准号:
10473864 - 财政年份:2016
- 资助金额:
$ 31.59万 - 项目类别:
相似海外基金
Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
- 批准号:
2901112 - 财政年份:2024
- 资助金额:
$ 31.59万 - 项目类别:
Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
- 批准号:
485504 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
- 批准号:
495593 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
- 批准号:
485322 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
- 批准号:
493135 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
- 批准号:
493526 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
- 批准号:
10659658 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
- 批准号:
10723233 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
- 批准号:
10723861 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
- 批准号:
10586398 - 财政年份:2023
- 资助金额:
$ 31.59万 - 项目类别: